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Gastrointestinal angiodysplasias may cause anemia. Quality of life (QoL) is a valid patient
reported outcome and improvement of QoL represents an important treatment goal. There
is a paucity of data on the effect of angiodysplasias on QoL. Therefore, we aim to evaluate
QoL and fatigue in angiodysplasia patients. We performed a cross-sectional patient-
reported outcome study. We included patients with endoscopy proven angiodysplasias and
measured QoL with Short Form-36 and level of fatigue using Multi Fatigue Inventory-20. We
distinguished three subgroups of patients according to disease severity: 1) with treatment
for angiodysplasias, 2) without treatment for angiodysplasias and 3) without recent hospital
visits. The primary outcome was the physical component summary (PCS) score on the SF-
36. Multivariate regression analysis were performed to correct for differences at baseline. A
total of 144 patients completed the questionnaires (response rate = 62%; mean age 68
years; 65% men). Angiodysplasia patients have a significant lower PCS compared to the
age-matched general population (respectively 41.0 vs. 43.3, p = 0.01). Disease severity is
independently associated with a negative outcome on QoL (ß -4.6, 95% CI -7.8–-1.3). Simi-
larly patients score lower on multiple QoL subdomains, i.e. role limitations due to physical
health problems (40.8 vs. 44.0, p<0.01), general health (39.7 vs. 47.3, p<0.01). Angiodys-
plasia patients are more fatigued compared to the general population (male 56.1 vs. 48.5,
p<0.01, female 59.2 vs. 51.5, p = 0.01). In conclusion, angiodysplasias are independently
associated with clinically significant impairments in multiple domains of health-related QoL,
especially in measures of functional limitation.
Introduction
Angiodysplasias are defined as abnormally dilated mucosal veins that portend gastrointestinal
(GI) bleeding. The prevalence of GI angiodysplasias in the general population is unknown, but
it is seen in around 2% of the population subjected to colonoscopy [1]. Known risk factors are
higher age, aorta stenosis, chronic kidney disease and Von Willebrand disease [2]. The spec-
trum of the angiodysplasia disease phenotype is wide and ranges from absence of symptoms to
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chronic anemia with frequent red blood cell transfusions and hospitalizations. Anemia is asso-
ciated with adverse outcomes including functional decline, disability, morbidity and mortality
[3].
Conventionally, angiodysplasia related bleeding and associated morbidity are used to define
clinical outcomes: i.e. hemoglobin levels, rebleeds, need for endoscopic intervention [4, 5].
Intuitively, improvement of anemia as a response to endoscopic intervention might confer
benefits for patients but measuring hemoglobin levels does not necessarily capture how
patients actually feel and can be seen as a surrogate outcome. Patient reported outcomes
(PRO’s) are multidimensional, unique indicators of the impact of disease on an individual
patient [6]. Health related quality of life (QoL) is a PRO which represents the patient’s general
perception of the effect of illness on various physical and social aspects of life. It is increasingly
recognized that restoration of decreased QoL is an important treatment goal and bonafide out-
come in clinical research [7]. There is a paucity of literature on QoL in angiodysplasia patients,
but it is known that chronic anemia decreases QoL and that severe fatigue specifically impacts
QoL in anemic patients [8].
Based on the prevalence of anemia and the tendency of angiodysplasia bleeding to recur, we
hypothesize that angiodysplasia patients will have a reduced health-related QoL and higher
levels of fatigue compared to the general population. Furthermore, we surmise that there is a
relation between angiodysplasia disease severity and QoL. The primary objective of this study
is to investigate health related QoL and fatigue in angiodysplasia patients in a cross-sectional
patient-reported outcome study. Our secondary objective is to evaluate possible differences in
QoL between angiodysplasia patients who received treatment and those who did not.
Methods
Study design and setting
We performed a cross-sectional patient-reported outcome study at the department of Gastro-
enterology and Hepatology of the Radboud University Medical Center Nijmegen, the Nether-
lands (S1 Table). Patients with endoscopy confirmed angiodysplasias were recruited into a
longitudinal observational cohort between January 2010 and March 2015, with a follow-up
until July 2016. We administered validated QoL and fatigue questionnaires in August and Sep-
tember 2016.
Participants
Inclusion criterion were age 18 years and one or more proven angiodysplasias, defined by
the attending endoscopist reporting the term ‘angiodysplasia‘, ‘angioectasia‘, ‘ectasia‘, ‘telangi-
ectasia‘ or ‘arteriovenous malformation‘ in reports of esophagogastroduodenoscopy, colonos-
copy, balloon assisted enteroscopy or video capsule endoscopy. Three subgroups of patients
were distinguished to reflect disease severity: 1) treatment in the year prior to the question-
naires, 2) without treatment in the year prior to the questionnaires, 3) without hospital visits in
the year prior to the questionnaires. The group with angiodysplasia patients without treatment
was further classified according to presence of anemia (defined as Hb<8.5 mmol/L for men
and<7.5 mmol/L for women). Subjects were required to read and understand Dutch language
to complete the two patient self-assessment questionnaires. Exclusion criteria were cognitive
impairment (e.g. severe dementia) or physical inability to complete the questionnaires. The
questionnaires were sent via e-mail or regular mail, depending on patient’s preference. There
were at least two attempts to contact eligible patients and one reminder in case of no response.
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MFI-20, Multidimensional fatigue inventory; MH,
Mental health; n, Number; PCS, Physical summary
score; PF, Physical functioning; QoL, Quality of
Life; RE, Role limitations due to emotional
problems; RP, Role limitations due to physical
health problems; SD, Standard deviation; SF, Social
functioning; SF-36, Short Form Health Survey; VT,
Vitality.
Outcomes
Based on the hypothesis that QoL in angiodysplasia patients will be determined by physical
rather than mental limitations, the primary outcome is the physical summary score (PCS) of
the SF-36. Secondary outcomes are subdomain scores of the SF-36 and fatigue assessed by the
MFI-20. The eight subdomains are: physical functioning (PF), role limitations due to physical
health problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning
(SF), role limitations due to emotional problems (RE), and mental health (MH).
Measurements
Baseline measurements including patient and disease characteristics were extracted from the
electronic patient report system. Two patient self-assessment questionnaires, the SF-36 and
MFI-20, were used to measure the health related QoL and level of fatigue respectively [9, 10].
Two overall scores can be generated from the eight subdomains of the SF-36: the PCS and
mental summary score (MCS). A higher score on the 0–100 scale corresponds to a better QoL.
The SF-36 questionnaire has been extensively validated in several populations [11–13].
The MFI-20 has shown to have a good reproducibility and internal consistency among dif-
ferent patient populations [10, 14, 15]. Construct validity was demonstrated to be sufficient, by
comparing MFI-20 to several other questionnaires such as the SF-36 and the Fatigue Assess-
ment Scale [15, 16]. The MFI-20 consists of 20 items each having a 5-point Likert scale. A
higher score reflects a higher level of fatigue.
Sample size calculation
Based on previous literature the mean age in our study was ought to be>65 years [17]. There-
fore, the mean PCS for the general population with age 65–74 years (PCS = 43) was used [18].
As there is no previous literature on QoL in angiodysplasia patients, the effect size was based
on studies in patients with chronic kidney disease and anemia [8, 19]. With a power of 0.95, a
level of significance of 0.05 and a mean score on the PCS of 38 (compared to 43) with a SD of
10, the sample size was ought to be 88 patients.
Statistical analysis
Descriptive statistics were used to describe patient and disease characteristics. Categorical vari-
ables are expressed as percentages and continuous variables are expressed as mean ± standard
deviation (SD) or as median with range for non-normal distributed variables. Differences in
baseline characteristics were investigated with Chi-square testing.
To deal with missing data in the SF-36, we used personal mean score imputation of subdo-
main means, justified for subdomains missing < 50% [20]. Missing questions in the MFI-20
where imputed with the contrary formulated question. When there were >50% missing for
the SF-36 or missing the contrary question for the MFI-20, the patient was excluded from
analysis.
We used United States of America (USA) population norm values for the SF-36 and Ger-
man population norm values for the MFI-20 both corrected for age (age group determined
based on mean age of our included patients) [21]. Previous studies justify the use of USA
norm values for the Dutch population on the SF-36 [22]. One-sample t-tests were used to com-
pare these general population norm values with the study population to assess our primary
aim. One-way independent ANOVA with post-hoc Tukey testing was used to compare the
PCS, subdomain scores and level of fatigue between the three subgroups of patients: 1) treat-
ment, 2) non-treatment, and 3) patients without hospital visits in the past year. This statistical
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method was also used to investigate the differences on PCS between treated patients and ane-
mic / non-anemic patients in the non-treated group.
Finally, we performed multivariate linear regression analysis to correct for baseline differ-
ences (i.e. comorbidities) between the subgroups for the primary outcome. QoL is strongly
correlated with age and a small (not statistical significant) difference between groups could be
of influence. Therefore, we included age in the adjusted analysis for the primary outcome. A
two-sided tested p-value0.05 was considered statistically significant. The analyses were per-
formed using SPSS Statistics software version 22.0 (IBM, Armonk, NY, USA).
Interpretation of the results
PRO’s were interpreted by two important tools: the minimal clinically important difference
(MCID) and Cohen’s standardized effect size. The MCID is defined as the smallest difference
in a score which patients perceive as beneficial and which would mandate a change in patient
management. For the SF-36 the MCID ranges between 3–5 points [23, 24]. Standardized effect
size measures are helpful when the metrics of variables that are studied have no intrinsic mean-
ing. The Cohen’s standardized effect size is defined as the mean difference divided by the SD.
Effect sizes of 0.2–0.5 are considered as ‘small’, 0.5–0.8 as ‘moderate’, and> 0.8 ‘large’ [25].
Ethical considerations
Oral informed consent was obtained. The medical ethical committee CMO Arnhem—Nijme-
gen concluded that this research is exempt from Dutch national legislation for medical scien-
tific research involving humans in view of the minimal burden of two questionnaires.
Results
Participants
We identified 301 patients with proven angiodysplasias of which 69 were excluded based on:
deceased at the time of survey (n = 63), severe dementia (n = 4), severe psychiatric disorder
(n = 1) and physical inability due to severe Parkinson disease (n = 1). We failed to establish
contact with 39 eligible and 18 patients did not want to participate. In total 175 patients gave
informed consent and 155 patients returned the questionnaires (S1 Fig). Eleven SF-36 ques-
tionnaires had to be excluded due to>50% missing, and one more could not be included for
MFI-20 analysis. Therefore, 144 (response rate 62%) patients are analyzed for the SF-36 and
143 (61%) for the MFI-20 (S1 Dataset).
Disease severity subgroups consisted of patients treated (n = 27), not treated (n = 58), and
patients without recent hospital visits (n = 45). Fourteen patients could not be included in the
subgroup analysis due to follow-up in another hospital. Additional subdividing led to 39 non-
treated patients without anemia and 19 (41% of the patients with anemia) non-treated patients
with anemia.
Baseline characteristics
The majority of responders are men (65%) and the mean age was 68 years. Gender, valvular
heart disease, anticoagulant use and multiple angiodysplasia lesions were not equally distrib-
uted between subgroups (Table 1). These differences reflect that these variables constitute risk
factors for symptomatic angiodysplasia disease [1, 17]. There were no significant differences
between the subgroups in ischemic heart disease, diabetes mellitus, chronic obstructive pulmo-
nary disease, liver cirrhosis, congestive heart failure, or cerebral vascular accident.
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Angiodysplasias were most frequently located in the colon (n = 90, 69%) with a mean number
of 2.4 (SD 3.2) angiodysplasias per patient.
Primary outcome
Our cohort of angiodysplasia patients (n = 144) have a significant lower PCS score relative to
the general population (respectively mean 41.0 vs. 43.3, p = 0.01). However, this difference
does not reach MCID and has a small effect size (effect size: 2.3/10.8 = 0.21). Focusing on the
three subgroups (Fig 1), we see this is based on a significant lower PCS in the non-treatment
and treatment group compared to the general population (respectively 39.9 vs. 43.3, p = 0.01
and 34.4 vs. 43.3, p<0.01) as the patients without hospital visits have a non statistical signifi-
cant higher PCS score than the general population (46.1 vs. 43.3, p = 0.06). The differences
between the non-treated and treated patients and the general population for PCS (resp. 3.4
and 8.9 points) exceeds the MCID threshold with a respectively small (3.4/10 = 0.34) and large
effect size (8.9/10.3 = 0.86), which suggest that it bears clinical relevance.
When we adjust the primary analysis of PCS for differences in baseline characteristics, the
variables age, gender, valvular heart disease, anticoagulant use and number of angiodysplasias
are included in the multivariate linear regression model. The association of disease severity
covered in the subgroups treated, not treated and no recent hospital visits, is despite correction
of these factors independently negatively associated with PCS (ß -4.6, 95% CI -7.8–-1.3,
p = 0.006). However, the negative impact of angiodysplasia disease becomes smaller than in
univariate linear regression due to the influence of the comorbidities (ß -5.9, 95% CI -8.2–-
3.5). The interpretation of the beta coefficient is that the treated group in general scores -4.6
points lower on PCS as the non-treated group, which scores -4.6 points worse than the no-hos-
pital visits group.
Comparing the three subgroups with each other, the no-hospital visits patients have a sig-
nificant higher PCS score compared to the non-treatment and treatment groups (respectively
46.1 vs. 39.9 and 34.4, p = 0.01 and p<0.01). However, the PCS of the non-treatment group is
not statistically significant higher than the treated patients (39.9 vs. 34.4, p = 0.051).
Secondary outcomes
Subdomain analysis for QoL. The study population of all angiodysplasia patients
(n = 144) have compared to the general population a significant lower score on the following
Table 1. Descriptive data of all responders and comparison of asymptomatic versus symptomatic responders.
Baseline characteristics No hospital vistis Non-treatment Treatment P-value
Age—mean (±SD) 66yr (±10) 67yr (±11) 71yr (±9) 0.14
Gender: male—n (%) 33 (73) 38 (66) 12 (44) 0.04
Comorbidity—n (%)
Valvular heart disease 5 (11) 4 (7) 7 (26) 0.04
Chronic kidney disease 3 (7) 7 (12) 5 (19) 0.31
Anticoagulant use—n (%) 13 (29) 18 (31) 19 (70) <0.01
Number of angiodysplasias -mean (±SD) 1.5 (0.9) 1.9 (1.2) 5.3 (6.1) <0.01
Angiodysplasia location
Colon 36 (80) 35 (60) 19 (70) 0.10
Small bowel 5 (11) 12 (21) 8 (30) 0.14
Stomach 3 (7) 8 (14) 3 (11) 0.51
Total n = 45 n = 58 n = 27
https://doi.org/10.1371/journal.pone.0177522.t001
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QoL subdomains: MCS (48.2 vs. 52.7, p<0.01), RP (40.8 vs. 44.0, p<0.01), GH (39.7 vs. 47.3,
p<0.01), SF (43.7 vs. 47.6, p<0.01), RE (44.2 vs. 48.1, p<0.01) and MH (47.6 vs. 51.8, p<0.01).
No significant differences were found in PF, BP and VT.
Comparing the subgroups separately with the general population, we again see the differ-
ences for the overall angiodysplasia group are mainly based on the non-treatment and treat-
ment subgroups, with the non-hospital visit group continuously scoring higher on the 8
subdomains (Fig 2). The non-treatment group have a significantly lower score compared to
the general population on GH (47.2 vs. 38.3, p<0.01), SF (47.6 vs. 42.7, p<0.01), RE (48.0 vs.
43.2, p<0.01), MH (51.8 vs. 48.2, p = 0.02). As last, the treatment group have a significantly
lower score compared to the general population on PF (41.7 vs. 33.6, p<0.01), RP (41.7 vs.
36.3, p = 0.02), GH (47.2 vs. 34.8, p<0.01), VT (49.9 vs. 43.7, p<0.01), SF (47.6 vs. 41.5,
p = 0.01), RE (48.0 vs. 42.5, p = 0.02), MH (51.8 vs. 46.9, p<0.01).
Fig 1. Comparison of SF-36 physical component scale (PCS) for subgroups. Boxes with whiskers
display median and interquartile percentiles of subgroups, + sign indicates mean. Dotted line represents
mean general population. Asterisks point out significant differences (p<0.05).
https://doi.org/10.1371/journal.pone.0177522.g001
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Comparing the three subgroups there are larger differences in scores assessing physical sub-
domains such as PF, RP and GH (Fig 2), with the treated group scoring worse.
Level of fatigue. Angiodysplasia patients have significant higher levels of fatigue com-
pared to the general population (respectively male 56.1 vs. 48.5, p<0.01, female 59.2 vs. 51.5,
p = 0.01). This difference has a small effect size (Fig 3: men = 0.43 and women = 0.39). The
treatment subgroup is the only subgroup with a significant higher level of fatigue compared to
the general population for males (resp. 63.1 vs. 48.5, p<0.01) and females (resp. 66.1 vs. 51.5,
p = 0.01). This difference has a large effect size (men = 1.16 and women = 0.76).
Additional non-treatment subgroup analysis QoL. To investigate the effect of anemia in
the non-treated group on the QoL, the non-treated group was dichotomized according to pres-
ence of anemia (Fig 4). The patients without anemia have a significantly higher PCS score
compared to the non-treated patients with anemia and the treated patients (resp. 43.1 vs. 33.2
and 34.4, p<0.01 and p<0.01).
Discussion
The results of this cross-sectional study show that the presence of GI angiodysplasias is associ-
ated with a decreased QoL compared to the general population. Angiodysplasia patients have a
lower self-rated QoL and higher fatigue levels, and particularly the physical component of QoL
is significantly reduced. Moreover, we found a progressive decrease in QoL that corresponds
with disease severity. Finally, the QoL between treated patients and those not treated with ane-
mia is similar. This supports the relevance of a structured approach and suggest that iron sup-
plementation in patients with angiodysplasias and mild anemia is warranted. Treatment of
mild anemia in angiodysplasia disease is often withheld (41%).
To investigate whether a decreased QoL in our study population depends on co-existing
co-morbidity, we performed a multivariate regression analysis that corrected for differences in
co-morbidities at baseline. It was clear that angiodysplasia disease severity is an independent
variable that impacts health-related QoL.
Fig 2. Display of all SF-36 domain scores for the different subgroups. Physical functioning (PF), Role limitations caused by Physical health
problems (RP), Bodily pain (BP), General health (GH), Vitality (VT), Social functioning (SF), Role limitations caused by Emotional health
problems (RE) and Mental health (MH). Statistical significant (p<0.05) differences compared to general population are shown for each subgroup
with the following symbols. No hospital visits: ^, non-treatment: *, treatment: +.
https://doi.org/10.1371/journal.pone.0177522.g002
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The decrease in PCS associated with angiodysplasias is comparable to that seen in other
populations such as the elderly with anemia, [8] congestive heart failure or patients with ane-
mia due to chronic kidney disease [26]. This indicates that anemia in symptomatic angiodys-
plasias impacts QoL to a similar level as other chronic diseases. The MCID data in relation to
the effect sizes suggests that our findings bear clinical relevance.
The present study has several limitations. First, this is a single center study with retrospec-
tive data collection of the clinical data, e.g. medical history and treatment. This could intro-
duce reporting bias for the variables that have been retrospectively assessed (i.e. not our
primary endpoint). Second, SF-36 and MFI-20 are tools to measure health-related QoL and
level of fatigue respectively. Addition of the Functional Assessment of Cancer Therapy-Ane-
mia (FACT-An) questionnaire, specific for anemia would have been desirable. However, this
Fig 3. Comparison of MFI-20 scores for males (left) and females (right). Boxes with whiskers display median
and interquartile percentiles of subgroups, + sign indicates mean. Dotted line represents mean general
population. Asterisks point out significant differences (p<0.05).
https://doi.org/10.1371/journal.pone.0177522.g003
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tool is not available in a validated Dutch version. Third, the definitions used to classify the dis-
ease severity subgroups (i.e. treatment in the last year) are based on consensus meeting in view
of the absence of published criteria. Fourth, categorizing of our cohort in subgroups resulted
in a small number of patients compromising the study power. Last, similar to all questionnaire
studies response bias could be present. We have a response rate of 62% which is relatively high
[27–29]. Age, gender and past medical history were compared between responders and non-
responders to investigate differences that could have affected the results. Responders were
more often men than non-responders (respectively 64% vs. 49%, p = 0.02). Men tend to score
Fig 4. Comparison of SF-36 Physical component scale (PCS) for disease severity subgroups. Boxes
with whiskers display median and interquartile percentiles of subgroups, + sign indicates mean.
https://doi.org/10.1371/journal.pone.0177522.g004
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better on QoL questionnaires and therefore we assume this could have led to a small overesti-
mation of the QoL.
The strength of this study is that it measured QoL in angiodysplasia patients in a relatively
large cohort with the possibility to compare different disease severities. Moreover, our study
population was a heterogeneous angiodysplasia population. The risk of selection bias was low
due to a relatively high response rate and absence of clinical relevant differences between
responders and non-responders. Therefore, we think this study has a high external validity.
With a multivariate model we were able to correct for baseline differences in patient character-
istics between the disease severity subgroups, which increases the internal validity of this
study.
The results of this study highlight the need for additional clinical trials. For instance, a
study which evaluates different step-up treatment strategies in patients with angiodysplasias,
anemia and a reduced QoL. For such studies to have a true impact on practicing physicians,
they should reflect patient management in clinical practice. This would require a comparative
trial with a sufficient number of patients using practical inclusion criteria, clear crossing-over
criteria, a treatment failure scenario, and end-points that are clinically relevant in terms of
PRO’s. QoL measurements should be an integral part of the study.
In conclusion, this study shows GI angiodysplasias are independently associated with clini-
cally significant impairments in multiple domains of health-related QoL, especially in mea-
sures of functional limitation. Moreover, angiodysplasia patients experience a higher level of
fatigue compared to the general population. We encourage future research investigating treat-
ment strategies in angiodysplasias to take the patient’s perspective into account with the inclu-
sion of PRO’s such as the SF-36.
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